# Smiths Group All sites in China now reopened and operating at close to normal levels

- Link: https://www.directorstalkinterviews.com/smiths-group-all-sites-in-china-now-reopened-and-operating-at-close-to-normal-levels/412810543
- Published: 2020-03-31T07:21:22+01:00
- Author: Amilia Stone

**[Smiths Group plc](https://www.directorstalkinterviews.com/ftse-company/smiths-group/smin.l)**(
LON:SMIN) today released a trading update covering good growth for the six months
ended 31 January 2020 (“HY2020”) and the current impact of COVID-19; and announces
a delay to the separation of Smiths Medical. This announcement contains inside information.

Smiths was ready to publish its interim financial results today. However, it is 
complying with regulatory guidance to all UK-listed companies not to publish results
before 6 April 2020.

The key focus remains the safety of staff, business continuity, and actions to ensure
resilience in the context of market uncertainty.

**Good growth in the half**

·  Continuing Operations^(1) delivered underlying^(2) revenue growth for the 4^(
th) consecutive period, up +3%.  Reported revenue increased +8%, including the acquisition
of United Flexible.

·    John Crane revenue was up +6% on an underlying^(2) basis, with Original Equipment(“
OE”) up +8% as we continued to invest in growing the installed base.

·    Smiths Detection revenue grew +4% on an underlying^(2) basis, with OE up +8%
as we started to deliver previously announced contract wins.

·    Flex-Tek revenue increased +3% on an underlying^(2) basis, with growth in both
aerospace and industrial end markets.

·    Smiths Interconnect revenue declined (7)% on an underlying^(2) basis, driven
by previously communicated market weakness and a strong comparative period.  Lower
volumes, plus the relocation of production capacity, temporarily impacted margins.

·  Smiths Medical^(1) sustained its return to growth, with revenue up +1% on an 
underlying^(2) basis.

**Financial strength and resilience**

In HY2020 the Group again delivered strong cash generation, driven by operating 
cash conversion of 98%.

The Group has a strong balance sheet.  At the end of HY2020;

·    Net debt was £1.3bn (including £134m of leases following the adoption of IFRS16).
The ratio of net debt to EBITDA was 1.8 times. The average debt maturity is 4.6 
years, with no maturities until October 2022 and no covenant obligations.

·    Total liquidity headroom was in excess of £850m, including c.£250m of cash 
and an undrawn Revolving Credit Facility (“RCF”) of $800m (c.£600m), which does 
not mature before November 2023. The RCF carries one financial covenant: interest
cover equal to or greater than 3 times (HY2020 13 times).

It is our understanding that Smiths should also be eligible to access up to £600m
in funding via the Bank of England’s Covid Corporate Finance Facility (CCFF).

The Group’s pension plans are well funded, hedged and invested.  Taken together,
the two large UK defined benefit plans^(3 )had a surplus of £343m on an accounting
basis at the half year, and were fully funded on a technical provisions basis at
the last valuation.

Smiths also benefits from a purposefully resilient business model;

·     Leading positions in attractive markets

·     Capex-light, with a significant proportion of recurring aftermarket and service
revenues

·     A flexible cost base with c.60% of cost of sales being materials and other
variable costs

·     Serving critical industries with sustainable growth characteristics

·     Operational excellence

·     High structural cash conversion and strong balance sheet

**COVID-19**

Smiths activated its central crisis management team in January 2020 to drive the
Smiths response, first in China and now globally.

**People**

The health and safety of our people is paramount and we have put measures in place
to ensure that they remain safe. These measures include working from home for employees
who can,  alternating shift schedules and infection controls in manufacturing sites.

**Impact on trading year-to-date**

Group trading to the end of March was affected to some extent by early COVID-19 
disruption, which is now accelerating. In HY2020 only the Chinese operations of 
John Crane and Interconnect were disrupted. Orders that were due to ship in January
slipped into the second half.  All our sites in China have now reopened and are 
operating at close to normal levels. 

For the 8 weeks ended 28 March 2020, percentage revenue growth for Continuing Operations
and for Smiths Medical was mid-single digit.  

We have adopted measures to reduce cost and conserve cash including hiring freezes,
cancellation of discretionary expenditure and postponement of non-essential capex.
We have reinforced controls around receivables and payables, including cash tax (
corporate, indirect and payroll).

**Demand**

We are now seeing generally weaker demand, but with some mitigating factors;

·    Some customers have temporarily closed their facilities and have not been able
to accept delivery of equipment and services. 

·    Together with lower oil prices, energy customers have announced reductions 
in capital expenditure.  John Crane is not exposed to upstream oil & gas and has
a very strong order book, two thirds of which is aftermarket.

·    Passenger airports are closing or operating at significantly reduced capacity,
with knock-on impact on both OE and aftermarket revenue. However, Smiths Detection
has a record order book.

·    Smiths is making a significant contribution to meeting the global demand for
ventilators and other critical care devices. Smiths Medical is contracting with 
the UK Government for a significant ramp-up in production of its paraPAC plus^(TM)
ventilator.

**Supply**

We have experienced some disruption to supply chain and production;

·    As of 30 March 2020, sites accounting for more than 90% of manufacturing capacity
were open. However, because of infection control measures, sites are not running
at full capacity.

·    We are pre-emptively obtaining government authorisation for sites to remain
open where applicable, given the critical nature of our products.

·    A central coordination team is working in real time with operating units and
suppliers, to identify and resolve potential operations and supply chain issues.

**Forward guidance**

We are moving decisively on a number of fronts to address the near-term challenges.
Although we believe that we are in a strong position, it is too early to assess 
the full impact of COVID-19. Therefore we are withdrawing forward guidance for FY2020.

**Delay to the separation of Smiths Medical**

The previously announced separation of Smiths Medical was on track to be delivered
by the end of the first half of 2020. However, it is simply not practicable to complete
the separation in current circumstances.  Moreover, Smiths and Smiths Medical need
to focus on navigating the external challenges – including the delivery of ventilators
and other critical care devices.  Therefore, the Board has decided to delay separation
until conditions improve. The intent to separate remains unchanged.

**Dividend**

We remain confident in the strength of the Group’s financial position. However, 
at this time of unprecedented uncertainty, the Board considers it prudent not to
declare an interim dividend for HY2020. Recognising the importance of the dividend
to shareholders, the Board will review this decision again later in the financial
year as trading conditions become clearer.

**Strategic strength**

Beyond the near-term challenges of COVID-19, the Group is well placed to deliver
consistent outperformance;

·     Businesses well-positioned in long term, attractive growth markets

·     Products and services differentiated by market-leading, innovative technology

·     World-class operational excellence

·     A culture of innovation, entrepreneurship and relentless execution

·     Organic growth complemented by disciplined M&A

> **Andy Reynolds Smith, Group Chief Executive, commented:**
> “I have been inspired and am so proud of everything our people are doing around
> the world as we navigate Smiths Group through these unprecedented and challenging
> times. Smiths is a strong and naturally resilient business and we will come through
> this period well positioned for the future.  Our business benefits from financial
> strength, flexibility and a strong balance sheet with significant liquidity.  
> We are keeping our customers running, whilst staying safe and looking out for 
> each other through the disruption. I’m very grateful to our global team for all
> their efforts.”

**Definitions**

^(_1_)_ Continuing Operations exclude Smiths Medical which is accounted for as ‘
discontinued operations – businesses held for distribution to owners’._

^(_2_)_ Underlying modifies headline performance to adjust prior year to reflect
an equivalent period of ownership for divested businesses, and excludes the effects
of foreign exchange and acquisitions._

^(_3_)_ Smiths Industries Pension Scheme (SIPS) and TI Group Pension Scheme (TIGPS)._

Share on:
